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Abstract | MicroRNAs (miRNAs) are secreted by cells in vesicles, bound in a 
ribonucleoprotein complex or as free molecules. These miRNA secretion pathways 
are dysregulated in cancer, making miRNAs attractive candidate molecules for liquid 
biopsies. A number of studies have investigated the regulation of miRNA secretion 
into blood and urine and suggested that miRNAs are noninvasive diagnostic, 
prognostic and surveillance markers in urological carcinomas, and research in this 
area has increased over the past 5 years. However, methodological and analytical 
pitfalls exist and require addressing to enable future translation of the laboratory 
findings regarding miRNAs as biomarkers into clinical practice in bladder cancer, 
kidney cancer, prostate cancer and testicular cancer.  
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 The promise of microRNAs (miRNAs) in the diagnosis, prognosis and therapy for 
urological tumours has caused much excitement.1 The particular importance of 
miRNAs within the field of urology has been reflected in the rising number of annual 
publications on this topic indexed in the PubMed database, which has increased from 
132 in 2010 to an estimated 400 in 2016 (Fig 1). During this period a considerable 
increase in the number of articles regarding miRNAs occurred in relation to all articles 
concerning urological neoplasms from 1.06% in 2010 to an estimated 2.63% in 2016. 
Moreover, ~3.7% of all articles regarding miRNAs refer to urological neoplasms. This 
increased research effort, enabled by use of novel methodologies, such as more 
sensitive or single cell sequencing approaches, digital polymerase chain reaction 
(PCR) or different variations of crosslinking immunoprecipitation methods and state-
of-the-art bioinformatic facilities, has distinctly improved our understanding of the 
molecular processes that occur in urological tumours and also resulted in increased 
focus on the translational potential of miRNA research into clinical practice.  
MiRNAs have great potential as novel cancer biomarkers.2-6 In this Review  we 
provide an update on the use of miRNAs specifically within the blood and/or urine of 
patients with urological cancers as diagnostic, prognostic and predictive biomarkers. 
In particular, we discuss the origin of miRNAs in biofluids, their use as biomarkers 
and the qualitative and quantitative changes in miRNAs in biofluids of patients with 
bladder, kidney, prostate and testicular cancer.  
 
[H1] Biofluid miRNAs as biomarkers 
Molecular processes associated with tumour characteristics, such as tumour stage, 
grade, size, aggressiveness and metastasis, result in dysregulated miRNA 
expression profiles in cancer tissue. This dysregulation was reported in The Cancer 
Genome Atlas (TCGA) studies, which included most urological malignancies.7-11 
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Potentially, these molecular alterations in tumours are mirrored in biofluids, and can 
be easily detected in blood and urine12, providing the rationale for the potential use of 
miRNAs as noninvasive cancer biomarkers. According to Fuentes-Arderiu13, a 
biomarker is defined as a “human or animal biological property whose in vitro 
measurement or identification is useful for the prevention, diagnosis, prognosis, 
treatment, and follow-up of human or animal diseases, and for their understanding". 
Finding molecular markers for diagnosis, follow-up monitoring, therapy choice, 
response prediction and surveillance is of critical importance, especially with regards 
to personalized medicine.14 Personalized medicine aims to stratify patients into 
distinct molecular subtypes, which will allow to decide for the most suitable 
therapeutic approach to prevent unnecessary treatments with severe side effects. 
MiRNAs can be detected in biofluids as free (or naked) circulating miRNAs, 
bound to ribonucleoprotein complexes (especially Argonaute proteins), high-density 
lipoproteins or nucleophosmin or in extracellular vesicles, such as exosomes, 
microvesicles or apoptotic bodies (Fig 2).15-19 miRNAs that are bound, complexed or 
contained in extracellular vesicles are protected from degradation and, as a result, 
are stable in biofluids.20,21 The most extensively studied miRNA-containing vesicles 
are exosomes. Packaging of miRNAs into vesicles seems to be selective, as miRNA 
content in the secreting cells and in vesicles differ from each other.22 Exosomal 
secretion of miRNAs increases in metastatic cancer cells, suggesting they have a 
specific role in tumour progression.23 The precise function of secreted vesicles is still 
under discussion, but results show that miRNAs enable cells to communicate with 
each other.6,18,19 
Detecting miRNAs in biofluids is challenging and methodological pitfalls have 
to be taken into account. Factors that could affect miRNA measurements in the 
preanalytical, analytical and postanalytical phases of detection include the method of 
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sample collection, processing conditions, storage conditions, RNA isolation 
technique, quality control, quantification principle and the method of data evaluation 
(Box 1).24-28 Furthermore, the development and evaluation of a biomarker assay is a 
multistage process, including the identification of suitable markers in discovery 
phase, the development of specific, sensitive and robust assays and their validation 
in various steps (Box 2). The development of a marker assay depends on the specific 
clinical question and the distinct aspects for the respective tumour type must be 
considered. This process goes well beyond the development of pure diagnostic 
markers. For example, for prostate cancer, factors such as the identification of 
suitable markers for the surveillance of patients need consideration, to avoid 
overtreatment with the risk of adverse effects.5  
All these critical aspects should be considered as the basis for a continuous 
communication between laboratory and bioinformatics scientists, clinicians and 
statisticians in order to ensure reliable data for the clinical decision-making process. 
These characteristics are a useful starting point for the evaluation of the current 
status and future challenges regarding using miRNAs as biomarkers in biofluids.  
 
 
[H1] Biofluid miRNAs in bladder cancer  
The low diagnostic sensitivity of cytology for detecting low-grade bladder tumours as 
well as the inconvenience for patients and the cost of cystoscopy diagnosis and 
follow-up monitoring resulted in the development of numerous noninvasive urine-
based tests.29 These are, for example, FDA approved tests, such as the NMP22 test 
(based on the measurement of the nuclear mitotic apparatus protein 22 [NMP22]), 
the bladder tumour antigen (BTA) test (based on the detection of the human 
complement factor H-related protein) or the UroVysion assay (based on a 
fluorescence in situ hybridization assay of detecting chromosomal in exfoliated 
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bladder cancer cells). All these commercially available assays have limited clinical 
validity mostly due to their low diagnostic specificity with the consequence of high 
rate of false-positive results under benign urinary tract conditions such as infection, 
inflammation or haematuria.29 Thus, the dysregulation of miRNAs in bladder tumour 
tissue and its possible reflection in urine and in blood have been suggested as 
promising new biomarkers for bladder cancer.30 The European Association of 
Urology (EAU) guidelines on non-muscle-invasive urothelial carcinoma of the bladder 
define three main purposes in applying new molecular markers for bladder cancer: 
firstly, screening of the population at risk of bladder cancer; secondly, evaluation of 
patients with symptoms suspicious for bladder cancer; and thirdly, facilitated 
surveillance of patients with bladder cancer to reduce the number of cystoscopies.31 
Bladder cancer can be distinguished in to two different types, non-muscle-invasive 
bladder cancer (NMIBC) is confined to the mucosa or submucosa, in contrast to 
muscle-invasive bladder cancer (MIBC) that has invaded the muscle. In addition to 
the diagnosis of cancer, determining the recurrence and the risk of progression of 
NMIBC to MIBC are of clinical interest. For MIBC, events of progression and 
metastasis (which can change in response to the different therapy options) are 
connected to the clinical end points progression-free survival, cancer-specific survival 
and overall survival. NMIBC and MIBC differ particularly in their molecular 
characteristics.32 A legitimate hope exists that an miRNA pattern dependent on the 
progressive nature of the bladder cancer33 could be used as a diagnostic, prognostic 
and predictive marker through its reflection in biofluids. 
 
[H3] miRNAs in urine samples. 
In 2010, Hanke et al.34 published the first report on urinary miRNAs as diagnostic 
tools for bladder cancer. Since then, further studies have been published (Table 1).34-
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61 In general, retrospective observational studies in the form of case-control studies 
have been performed, mostly in single centres. Prospective cohort studies have been 
the exception. Furthermore, despite the urgent need for markers for surveillance of 
patients with bladder cancer, few studies investigating miRNAs in bladder cancer 
have addressed this issue.52 
The diagnostic capacity of miRNAs are promising with regards to the global 
discrimination criterion of an area under the receiver operating characteristics curve 
(AUC) >0.75 (Table 1).42,45,48,50,51 Moreover, some studies reported on the usefulness 
of miRNAs as prognostic markers, although there is no agreement on the use of 
specific miRNAs.41,51,52 The use of miRNA combinations seems to be more 
advantageous than that of single miRNAs.42,43,52,54 However, the lack of external 
validation of all miRNAs proposed as biomarkers prevents general conclusions on 
the clinical utility of miRNAs at present. In addition, factors such as differing study 
designs (in the relation to the objective of the study and the clinical heterogeneity of 
study cohorts — patients with MIBC or NMIBC were both included) and use of 
different urine test materials for miRNA measurements — urinary miRNAs were 
determined in native noncentrifuged urine, in sediment, in urine supernatant after first 
standard centrifugation and in extracellular vesicles like exosomes — make 
comparison difficult. In addition, the processing conditions for the preparation of test 
material were often not clearly reported. No consensus exists on what type of sample 
should be used, although test kits are commercially available for all these sample 
materials (from companies such as Norgen, Qiagen and Exiqon).45 Furthermore, the 
choice of which miRNAs to detect differed between each study. For example, in 
some studies miRNAs were selected for measurement in urine samples in relation to 
their differential expression in tumour tissue identified in external or investigators’ 
own previous studies. This approach might not result in the detection of the most 
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suitable biomarkers. miRNA secretion is a highly regulated process and the 
composition of miRNAs in biofluids and cells can differ greatly. Other authors decided 
on the panel of miRNAs according to the detection of released miRNAs in 
conditioned cell culture medium despite the fact that cell lines frequently differ in their 
molecular characteristics in comparison to the primary tumour cells. However, 
genome-wide discovery experiments in a first study phase, using sequencing or array 
technologies, and subsequent validations with individual RT-qPCR for each miRNA in 
the biofluid of interest are more meaningful and comprehensive.50,54,59 
Importantly, in most studies, the evaluation of the diagnostic validity of 
miRNAs was limited without consideration of the recommendations included in the 
EAU guidelines. Generally, direct comparison of the performance of miRNAs with 
conventional cytology or other urine tests was not performed, with the exception of 
studies by Sapre et al.52 and Eissa and colleagues.48 Sapre et al.52 calculated that 
their recommended miRNA monitoring set (diagnostic sensitivity 88%, diagnostic 
specificity 48% and negative predictive value 75%) could reduce the cystoscopy rate 
by 30%. Eissa et al.48 used an integrative approach combining cytology results with 
data regarding the expression of two miRNAs (miR-96 and miR-210) and the long 
noncoding RNA urothelial cancer associated 1 (UCA1) and achieved remarkable 
discrimination between patients with bladder cancer and those with negative 
cystoscopy results with an AUC value of 0.933. Thus, in contrast to these two 
examples, the real benefit of the miRNA measurements remains frequently unclear in 
several studies, but their effectiveness in comparison to standard tests should be 
disclosed when reporting study results. The Standards for Reporting Diagnostic 
Accuracy (STARD) guidelines recommend comparison between the reference 
standard and the new test for assessing the real benefit of the new marker assay.62 
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Haematuria is a key symptom of bladder cancer.31 Thus, miRNAs occurring in 
erythrocytes must be excluded as biomarkers for bladder cancer.61,63 However, 
several studies have investigated miRNAs that are obviously affected by haemolysis 
with regards to their levels, apparently without consideration of the potential for 
interference (Table 1). Thus, numerous miRNAs that have been suggested to be 
cancer-specific biomarkers in various studies are likely to reflect haematuria but not 
the dysregulation of miRNAs in bladder cancer tissue. 
 
[H3] miRNAs in serum and plasma samples. 
Current data and understanding regarding miRNAs in blood are similar to those 
regarding miRNAs in urine. To date, eight studies concerning miRNA levels in serum 
or plasma have reported (Table 1). Published in 2013, the first studies in this field 
measured selected miRNAs that had previously been found to be dysregulated in 
bladder cancer tissue. However, data from two studies published in 201554,59, used a 
genome-wide, array-based profiling discovery phase with subsequent validation 
phases and corresponding large training and validation cohorts. Their results can be 
robustly assessed concerning the diagnostic and prognostic potential of circulating 
miRNAs (Table 1). Du et al.59 achieved a global discrimination between control 
participants and patients with bladder cancer with an AUC value of 0.711, using the 
combination of miR-497 and miR-663b expression levels, which had been selected 
from eight differentially expressed miRNAs that had been identified in the discovery 
phase. These data were obtained using a two-phase validation method with separate 
training and validation cohorts. Jiang et al.54 applied a similar approach; however, 
they identified, based on sequencing data of pooled serum samples in a discovery 
phase, a robust panel of six miRNAs in a training phase with 120 patients and 120 
controls and a validation phase with 110 patients and 110 controls. Using the six-
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miRNA diagnostic set, the investigators were able to differentiate between patients 
with NMIBC and those with MIBC with an AUC value of 0.899. Furthermore, risk 
stratification of patients with NMIBC regarding tumour recurrence was achieved by 
using an additional two-miRNA prognostic panel.  
 
[H1] MiRNAs as biomarkers for bladder cancer 
Based on these results, miRNAs in urine and serum or plasma should be considered 
in further studies as potential biomarkers for bladder cancer. However, solving the 
numerous issues concerning the preanalytical and analytical conditions, as well as 
data analysis, study design and choice of miRNAs investigated, is essential before 
well-designed multicentre systematic studies are performed. Currently, the 
application of a diagnostic or prognostic test validated in external studies is not 
available for clinical practice. 
 
 
[H1] Biofluid miRNAs in kidney cancer  
The clinical management of patients with renal cell carcinoma (RCC) is mainly based 
on traditional clinicopathological and radiological examinations. However, the 
diagnostic, prognostic and predictive models that are based on these conventional 
data alone have limited accuracy and need improving.64 In contrast to other cancer 
types, robust noninvasive blood or urine biomarkers for all histological RCC subtypes 
are still lacking. Owing to these issues, the discovered effect of miRNAs on the 
initiation and progression of RCC has fuelled the desire to translate these new 
insights into novel miRNA-based biomarkers in biological fluids, such as blood and 
urine.  
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[H3] MiRNAs in serum, plasma and urine samples. 
Available studies concerning miRNAs as biomarkers for RCC have striking 
particularities in their designs, preanalytical conditions and analytical conditions 
(Table 2).65-76 Specifically, relatively few studies, including only one multicentre 
study67, have been conducted, and most studies did not perform an internal 
validation with a training and validation set or even an internal validation approach, 
such as bootstrapping or cross-validation. Moreover, all studies except one used 
serum as the source of RNA despite plasma being the blood component of choice 
since the release of miRNAs from blood cells such as the miRNA-enriched platelets 
into serum occurs during the coagulation process.77 Furthermore, collection 
processing was often incompletely described, and only one study73 controlled for the 
effect of haemolysis as an interfering factor in the miRNA measurements. In addition, 
different strategies were applied for normalizing RT-qPCR data and contrasting 
results regarding the regulation of miR-378, as example, were reported already in 
three studies.68,72,74 
All studies conducted to date were primarily focused on the diagnostic 
objective of discrimination between patients with RCC and healthy control subjects. 
The study cohorts consisted either of patients with only clear cell RCC (ccRCC)69-71,74 
— the subtype with the highest incidence — or combined with patients of papillary, 
chromophobe or sarcomatoid RCC.67,68,72,75 To date, no studies have been 
performed that investigate the clinical need for differentiating histological RCC 
subtypes from biofluid samples. Discrimination of RCC subtypes using miRNAs has 
already been achieved successfully using tissue samples and is important for the risk 
stratification of patients.78 The use of more than one miRNA is generally 
recommended to obtain improved accuracy and robustness of results.72,74 Some 
studies compared circulating miRNA data with the simultaneously acquired miRNA 
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profiling data of matched RCC and normal tissue.67,69,71 The observed changes in 
circulating miRNAs were not always concordant with the tissue expression levels67,79 
and association with clinicopathological factors like tumour stage and grade were not 
observed.69,71,72,75 Such differences should not generally be interpreted as a 
contradiction; such distortions between cellular and circulating markers are possible 
as the molecular releasing processes of the different miRNAs from cells into the 
extracellular compartment are highly regulated. This phenomenon is well-known for 
other biomarkers, such as enzymes and cytokines.80  
All but one of the single-centre studies reported acceptable discriminative 
abilities of different miRNAs with AUC values >0.75 (Table 2). However, the 
necessity of validating these results in independent validation cohorts became 
evident in a multicentre study.67 miR-1233 was the only miRNA out of seven potential 
candidates selected after discovery and verification phases that maintained different 
expression values between patients and control subjects in a validation phase. It had 
only an AUC value of 0.588 (95%CI 0.505–0.671) for independent study cohorts, 
which is lower than the AUCs that had been reported in studies without independent 
study cohorts.68,70,71  
In two studies, a decline in the concentration of miR-210 and miR-378 was 
observed after nephrectomy for treatment of RCC70,72, and both miRNAs were 
suggested as potential indicators of cancer recurrence in follow-up monitoring of 
patients with RCC. Only one study demonstrated that miRNA expression could 
function as an independent prognostic marker, in which an increased expression 
level of miR-221 was associated with poor overall survival.75 The predictive ability of 
a multivariate model that included tumour stage, Fuhrman grade and age ≥60 years 
was improved if the circulating miR-221 expression level was also included, 
demonstrated by the increase of the hazard ratio from 4.7 without miR-221 
13 
 
expression to 10.7 with expression included.75 However, another study investigating 
the diagnostic and prognostic utility of miR-221 and miR-378 did not verify this 
predictive ability.72 Thus, the evaluation of the potential of miRNAs as tools for risk 
stratification remains an important research goal. 
Gamez-Pozo et al.76 performed a particularly interesting study with regard to 
the use of miRNA signatures for personalizing treatment of metastatic RCC. The 
investigators examined the miRNA profiles of leucocytes in peripheral blood samples 
from patients receiving sunitinib for advanced RCC using microarrays. RT-qPCR-
validated predictive models were developed using differentially expressed miRNAs 
identified in the microarray analysis to distinguish patients with likely to be resistance 
to sunitinib before the treatment was started; these models were also informative with 
regards to overall survival. This promising approach already published in 2012 has 
yet to be verified in an independent study. 
Surprisingly, only one study using urine samples for miRNA analyses in 
patients with RCC has been reported. Von Brandenstein et al.65 measured miR-15a 
levels in whole-urine samples from patients with ccRCC. Distinctly higher 
concentrations were observed in ccRCC patients than in the urine of patients with 
benign renal oncocytoma, urinary bladder cancer or other, nonurological tumours. 
This increase was probably caused by an active release of miRNAs from the tumour 
cells in exosomes. After nephrectomy, the concentration of miR-15a decreased to 
nearly zero by the time of hospital discharge. Thus, careful assessment of the 
potential of miRNAs in urine and its fractions as diagnostic and prognostic markers 
for RCC is urgently required.  
 
[H1] MiRNAs as biomarkers in kidney cancer 
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In summary, despite some promising data no immediate prospect exists that miRNAs 
will be introduced as diagnostic or prognostic biomarkers either alone or in 
combination with the traditional clinicopathological factors in the routine management 
of patients with RCC. The lack of translational potential of miRNAs as biofluid 
biomarkers in RCC is probably a result of insufficient consideration of preanalytical 
and analytical variables, study heterogeneity and the retrospective nature of the 
reported studies. Also, studies using reference and target miRNAs that could be 
affected by haemolysis (such as miR-16, miR-21, miR-210 and miR-451)61,63 are 
possibly biased. Prospective studies are necessary and should consider all variables 
that could influence the detection of miRNAs in biofluids (Box 1).  
 
 
[H1] Biofluid miRNAs in prostate cancer  
The use of serum PSA concentration as a screening marker for prostate cancer has 
resulted in controversial recommendations and debates.81 One key point regarding 
the critical assessment of this marker is its limited ability to discriminate between 
aggressive tumours that need treatment and clinically insignificant tumours or benign 
prostatic diseases that do not require intervention but should undergo active 
surveillance.81 Consequently, current biomarker research is focused on the 
translation of the new insights into molecular alterations in prostate cancer82 into 
noninvasive biomarkers in biofluids, including miRNAs that would not have the 
disadvantages of PSA. Other purposes are the development of monitoring assays 
that reflect response to hormonal therapies, chemotherapeutic or radiotherapeutic 
options for prostate cancer treatment or improve prognostic information for both 
clinicians and patients.3,5 
 
[H3] miRNAs in blood, serum and plasma samples. 
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In 2008, Mitchell et al.20 presented the first data showing differing circulating miRNA 
concentrations in the serum of patients with metastatic prostate cancer in comparison 
with matched healthy controls. These findings triggered a storm of enthusiasm and 
resulted in a wave of subsequent studies and numerous reviews. To date, 37 reports 
investigating miRNAs in whole-blood samples, serum, plasma, peripheral 
mononuclear cells and exosomes have been published. Also, 10 articles have been 
published regarding urinary miRNAs in samples from patients with prostate cancer. 
(Table 3).20,83-126 
The starting points of these studies for the identification of useful miRNAs 
(such as a profiling discovery phase, dysregulated tumour tissue expression data, 
cell culture results or data in the literature) and the subsequent validation phase were 
different, as has been observed for studies regarding miRNA expression in other 
urological tumours. This disparity and the heterogeneity and size differences of study 
cohorts make a comparison of the data between studies difficult. However, an 
assessment of the numerous studies with regards to the translation of miRNA 
biomarker research into clinical practice is facilitated by taking into account 
assessment criteria (Box 2). This comparison is possible by comparing the results 
regarding the same miRNAs measured in different studies with broadly similar 
objectives. The most frequently investigated miRNAs were miR-141 (in 15 studies), 
miR-21 (in 10 studies), miR-375 (in eight studies) and miR-221 (in seven studies). 
For example, the usefulness of miR-141 as marker for early detection of prostate 
cancer was only found in two out of six corresponding diagnostic studies.121,126 In 
nine out of these 15 miR-141-studies, miR-141 was only evaluated as a marker of 
advanced or metastatic prostate cancer (Table 3).20,84,96,99,101,103,113-115 but was 
frequently, if at all reported, not better than the routine marker PSA.114,115,118 These 
data underline the fact that the clinical relevance of a marker can only be truly 
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assessed if studies with similar questions are compared: a useful diagnostic marker 
might be a useless prognostic marker and vice versa. Similarly, miR-21 proved to be 
unsuitable as an early marker in four studies (Table 3).88,100,102,122 In addition, serum 
miR-21 expression levels discriminated between localized and metastatic prostate 
cancer, but its differential diagnostic power assessed by AUC values was surpassed 
by the traditional prostate cancer marker PSA.118 By contrast, high levels of miR-21 in 
peripheral blood mononuclear cells in 75 patients with prostate cancer and 75 
controls were strongly associated with prostate cancer presence (AUC = 0.833), 
recurrence and metastasis, but corresponding data for PSA or the Prostate Health 
Index were not reported.123 miR-375 appears to be a specifically useful marker for 
prostate cancer. Two studies showed that use of miR-375 expression levels provided 
better discrimination between patients with prostate cancer and control subjects than 
PSA.113,120 miR-375 was also reported as a marker for metastatic prostate 
cancer96,118 and a prognostic marker for overall survival.124 However, two other 
studies did not find that this miRNA could be used as tool to discriminate between 
patients with a positive biopsy result and those with a negative result or between 
patients stratified as having low-risk or high-risk prostate cancer.88,121 These 
examples illustrate that results regarding the utility of specific miRNAs as biomarkers 
can be discrepant between various studies. These differences can be caused by 
differences in sample material and the study objective. Results published since 
2015111-113,120,121,123-126 (Table 3) report more promising diagnostic and prognostic 
data than earlier studies. One reason for this improvement could be that 
combinations of different miRNAs111,121, miRNAs in combination with other 
markers113,120 and miRNAs in blood cells123 or exosomes124 were investigated, rather 
than single miRNAs. However, the promising results of these studies are yet to be 
validated. 
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[H3] miRNAs in urine samples.  
In 2012, the FDA approved the Progensa PCA3 test that determines the ratio of PSA 
mRNA to the long noncoding RNA PCA3 in urine after standardized digital 
manipulation of the prostate for use in the decision-making process for repeat biopsy. 
Since then, several studies have been published that investigate the use of miRNAs 
in urine as predictive markers for positive biopsy results or the presence of high-risk 
cancer. However, results are divergent (Table 3)83-92 and no firm conclusions can be 
made regarding the utility of miRNAs in urine as biomarkers for prostate cancer. 
 
[H1] MiRNAs as biomarkers in prostate cancer 
Whether the determination of miRNA in blood, serum, plasma and/or urine of patients 
with prostate cancer could be a useful clinical tool remains an open question. The 
evaluation of the various studies according to the criteria for the development of a 
biomarker assay (Box 2) need to be considered. Specifically, the selection of miRNAs 
that are not affected by haemolysis is not only necessary for the determination of 
miRNAs in serum and plasma samples but also, in particular, in urine samples; 
generally, the urine-based studies did not consider that urine samples after digital 
rectal examination (DRE) might become dipstick-positive for haematuria, as has been 
observed in 30–40% of samples, depending on the examiner (K. Jung, unpublished 
work). However, several studies used haemolysis-affected miRNAs as their markers 
(Table 3) and these study results are probably biased. Moreover, different urine 
preparations (such as whole urine, sediment or supernatant after centrifugation either 
after DRE or without DRE) were used. In this situation, contamination of miRNA 
levels is possible from unspecific bladder cells that interfere with the detected 
concentration of miRNAs released after DRE from prostate tumour cells as exosomal 
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and protein-bound miRNAs or miRNAs in cells shed from the tumour.92 Moreover, 
most studies investigating the diagnostic and/or prognostic utility of miRNA 
biomarkers did not consider STARD or Reporting Recommendations for Tumor 
Marker Prognostic Studies (REMARK) guidelines.62,127 These guidelines require that 
results of the comparator test (the reference standard) for the diagnostic objective 
and results in relation to the standard prognostic variables for predicting clinical end 
points should always be reported, in addition to the results regarding the biomarker 
assay examined. Several studies were not appropriately designed for answering the 
question of whether miRNA biomarkers enable incremental information beyond the 
conventional standards for predicting biopsy outcome or disease progression. This 
inadequacy is evident in urinary and blood miRNA studies as PCA3 in urine and the 
best serum PSA derivative, the Prostate Health Index, were rarely used as 
comparator tests.86,92 Studies that applied multivariate Cox regression analysis for 
the assessment of clinical usefulness of miRNA concentrations as independent 
markers for predicting biochemical recurrence after prostatectomy or other outcomes 
are currently the exceptions.104,111,124  
 
 
[H1] Biofluid microRNAs in testicular cancer 
In 2010, the overexpression of the miRNA clusters miR-371–373 and miR-302–367 
in all testicular cancers and their association with stem cells, as previously 
described128,129, was reaffirmed.130 Subsequently, the expression levels of these 
tissue-based signatures were measured in serum.131-136 These liquid biopsy data 
confirmed the potential utility of miRNA measurements for discriminating patients with 
seminoma or those with nonseminoma from healthy control subjects. A selected set 
of four miRNAs (miR-371a-3p, miR-372, miR-373 and miR-367) present in the two 
clusters that showed the highest discriminative power for diagnosis and follow-up of 
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cancer, combined with reference miRNAs (miR-20a and miR-93) and spike-in 
controls was developed as the ‘targeted serum miRNA assay’ (TSmiR).136 This test 
showed a distinctly higher diagnostic sensitivity of 98% in a cohort of 80 patients with 
testicular cancer and 47 control subjects from five different groups than the standard 
markers α-fetoprotein and β-human chorionic gonadotropin, which had sensitivities of 
only 36% and 57%, respectively. In addition, serum levels of these four miRNAs 
normalized after orchiectomy and decreased after chemotherapy in patients with 
metastatic disease, and miR-371a-3p was the most sensitive marker for detecting 
these changes.134,136 Two independent studies, confirmed these promising results for 
miR-371a-3p as a biomarker for testicular cancer; however these reports only 
included a limited number of participants.132,133 A simplified assay for analysing miR-
371a-3p without endogenous controls was recommended to reduce laboratory work, 
analytical time and costs.137 Results of another study confirmed the discriminative 
ability of serum miR-371a-3p and miR-372 concentrations and also identified 
numerous novel discriminative serum miRNAs (miR-511, miR-26b, miR-769, miR-
23a, miR-106b, miR-365, miR-598, miR-340 and let-7a), which were identified using 
a high-throughput profiling system, but did not validate the results.131 Ruf et al.138 
evaluated next-generation sequencing miRNA data obtained from RNA isolated from 
whole-blood samples from patients with seminoma using support vector machines as 
classifier method with different combinations of two miRNAs to discriminate between 
metastasized and nonmetastasized patients. Their approach combined simplification 
of sample collection with sophisticated technology and data analysis, which are 
important landmarks for translational research. Overall, 33–35 miRNAs with 
differential expression were identified and complete discrimination of patients with 
metastasized seminoma from those with nonmetastasized seminoma was achieved 
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using numerous combinations of pairs of these miRNAs, for example miR-18a and 
miR-532, miR-19b-1 and miR-342 or miR-28 and miR-574.  
 
[H1] MiRNAs as biomarkers in testicular cancer 
In summary, the current data considered together and despite the limited sample 
sizes in the individual studies provide convincing evidence for the use of miRNAs as 
biomarkers for testicular cancer. Supported by further positive data from an ongoing 
prospective multicentre study of the German Testicular Cancer Group (AUO No. AH 
14/15-MicroRNA, German Association of Urogenital Oncology; http://auo-
online.de),the introduction of miRNA measurements is anticipated for the clinical 
management of patients with testicular germ cell tumours in the near future. 
 
[H1] Future perspectives  
The number of studies investigating circulating miRNAs in urological tumours has 
increased greatly in the past 5 years. Next-generation sequencing has become faster 
and more affordable enabling rapid systematic sequencing of samples in large-scale, 
multicentre studies, facilitating biomarker research. Current studies confirm that a 
noninvasive measurement of circulating miRNA concentrations in urological 
carcinomas is possible and that dysregulation of miRNAs is specific for patients with 
cancer. A number of study results show that the expression changes that have been 
described in tissue are not always reflected in blood or urine, highlighting that 
regulated secretion pathways exist. Systematic multicentre studies, addressing the 
specific miRNA expression patterns (as have been performed in tissue samples) are 
missing in biofluids. Without these unbiased screening studies, some potential 
markers might still be undiscovered. The comparability and translational potential of 
the current studies is limited, even though the number of studies is increasing. The 
21 
 
reasons for these discrepancies are the existing preanalytical and analytical 
differences and the heterogeneity of tested specimens. 
The different miRNA secretion pathways influence which samples are most 
suitable for marker detection. Few studies have addressed which miRNA component 
in biofluids (such as free miRNA, exosomal miRNA or miRNA bound in 
ribonucleoprotein complexes) is the most suitable for sensitive and robust marker 
detection. However, most circulating miRNAs are bound to proteins or packaged in 
vesicles and free circulating miRNAs only have limited stability, therefore, 
compartmentalized miRNAs seem to be the most suitable tumour markers.2 
No consensus exists regarding which miRNA isolation method is most suitable 
for miRNA detection in serum, plasma or urine samples, and different preparations of 
blood (such as plasma, serum or whole blood) or urine (such as whole urine, 
supernatant or sediment taken after or without DRE) have been used. Other 
important analytical factors include haematuria and haemolysis. Follow-up studies 
must stringently control miRNA expression to mitigate the effects of haemolysis in 
order to exclude false-positive results. Analytical issues such as sensitivity, 
specificity, accuracy and robustness of the detection assays have not been 
sufficiently studied and need to be addressed. Next-generation sequencing and 
digital PCR might prove to be more accurate and sensitive than conventional miRNA 
expression profiling by microarray and RT-qPCR. A comparison of miRNA 
sequencing, microarray or RT-qPCR profiling indicates that each method has specific 
weaknesses, highlighting that which method to use must be considered with regards 
to the specific study design and end point.139 
Validation of miRNA expression in independent cohorts and multicentre 
studies is limited. Additional prospective, multicentre studies, which stringently control 
preanalytical and analytical conditions, are necessary. In these studies, the end 
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points should be clearly defined and should address the specific clinical needs, such 
as surveillance markers in bladder cancer to reduce the need of invasive cystoscopy, 
stratification of aggressive prostate tumours or predictive markers in kidney cancer, 
which are important clinical issues that have not been sufficiently addressed. These 
studies would also enable the inclusion of miRNA markers into multivariate models. 
The resulting models should be compared with current standard markers. Without the 
existence of these studies, conclusive results on single miRNAs or miRNA 
combinations as diagnostic, prognostic or predictive markers is not possible. 
 
Conclusions Circulating miRNAs are promising marker candidates for urological 
tumours. In testicular cancer particularly, a number of studies have good overlap in 
regard to the specific miRNA markers enabling comparison of the data and speedy 
translation of miRNAs as diagnostic markers into clinical practice. In bladder, kidney 
and prostate cancer, further studies are needed to address the methodological 
differences and large prospective studies concerning the respective clinical questions 
should be initiated to discover the usefulness of miRNAs as biomarkers in biofluids. 
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Review criteria 
A PubMed search was performed for original articles recorded in the database from 2010 to 
February 2016. The MeSH term "MicroRNAs" combined with the search string ["microRNAs" 
OR "microRNA" OR "micro-RNA" OR "micro-RNAs" OR miRNAs"] both alone and in 
combination with the MeSH terms "prostatic neoplasms", "kidney neoplasms", "urinary 
bladder neoplasms" and "testicular neoplasms". The urological MeSH terms were always 
linked with the corresponding keywords "prostate cancer", "renal carcinoma", "bladder 
cancer" or "testicular cancer" using the Boolean operator "OR" to improve the search 
strategies. In addition, reference lists of the identified articles and corresponding reviews 
were searched to ascertain further relevant publications. 
 
Key points 
• Several hundred miRNAs occur in biofluids as free molecules or are secreted in 
vesicles and bound in a ribonucleoprotein complex. The secretion of miRNAs into 
biofluids is dysregulated in cancer making miRNAs potential noninvasive tumour 
biomarkers 
• Studies performed on samples from patients with urological carcinomas suggest 
that miRNAs in blood, serum, plasma and urine can be applied as novel 
diagnostic, prognostic and surveillance biomarkers 
• Inconsistent and contradictory results from studies in bladder, kidney and prostate 
cancer impede translation of miRNA measurements into routine clinical practice, 
but a clinically useful signature confirmed in several studies has been developed 
for testicular cancer  
• Preanalytical, analytical and postanalytical differences as well as insufficient power 
and the heterogeneity of studies are the main factors in shortcomings in this 
research field 
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• Prospective, multicentre studies that consider all these deficiencies in their design 
are necessary to assess the real clinical benefit of miRNA measurements in the 
biofluids of patients with urological carcinomas 
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Box 1 | Variables influencing the determination miRNAs in blood samples‡ 
 
Preanalytical phase 
 Sample collection 
● Method of blood collection (aspiration or vacuum extraction systems) 
● Type of collection devices for serum (with or without enhanced coagulation using silicagel or 
kaolin) or plasma (using citrate, EDTA or heparin as anticoagulants) in different tubes (glass or 
plastic tubes, with gel separation) 
 ● Haemolysis effect (inadequate blood sampling, sample mixing) 
 ● Presence of endogenous inhibitors 
  
 Processing conditions 
● Time span between venipuncture and centrifugation 
 ● Centrifugation conditions (forces, time, repeat centrifugation) 
 ● Separation of serum or plasma from blood clot 
  
 Storage conditions 
● Temperature (long-term storage at -80 °C preferred) 
  
Analytical phase 
 RNA isolation protocols  
● Use of different sample volumes 
● Type of RNA isolation procedure with manufacturer's specifics (such as Trizol, column-
based or bead-based methods with or without genomic DNA removal, carrier addition, and 
enrichment of small RNA fraction) 
 ● Elution with different solutions and volumes 
  
 RNA quality control 
● Absorption ratios 260:280 nm and 230:260 nm; RNA integrity number or RNA quality 
indicator 
  
 Quantification principles 
● Different methods for analysing with different sensitivity and/or specificity (different array 
platforms, different sequencing methods and different RT-qPCR principles [such as Life 
Technologies, Qiagen, Exiqon and Nanostring] based on different complementary DNA 
synthesis conditions with or without preamplification and quantitative PCR methods [DNA-
binding dyes or probes])  
 Digital PCR 
 ● Different instruments associated with various software 
  
Postanalytical phase 
 Data evaluation 
● Different normalization strategies (endogenous reference genes, spike-in controls, absolute 
quantification, relation to starting sample volume, global mean or median approach) 
 
‡ Modified from Ralla, B. et al. Crit. Rev. Clin. Lab. Sci. 51, 200-231 (2014) . EDTA, 
ethylenediaminetetraacetic acid; RT-qPCR, reverse-transcription quantitative PCR. 
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Box 2 | Development phases of biomarker assays for clinical practice 
 
Discovery and selection of potential biomarkers: 
Identification and selection of differentially expressed miRNAs according to the 
objective based on various principles: 
●  Genome-wide profiling in the corresponding sample material on array or 
sequencing basis 
●  Selected differentially expressed miRNAs identified in the cancer tissue  
 ● Released miRNAs from corresponding cancer cell cultures into 
conditioned medium 
 ●  Data from the literature 
 
Assay setup and performance control: 
All working steps (preanalytical, analytical, postanalytical) of the determination 
of the selected biomarker should be established for a robust, accurate and 
reproducible assay or at least a fit-for-purpose assay 
 
Validation by clinical assessment 
Confirmation of utility as a screening, diagnostic, prognostic and/or predictive 
marker in retrospective and/or single-centre studies with internal validation 
 
Validation by clinical usability  
Confirmation in prospective, multicentre studies as advantageous or at least 
equivalent in comparison with standard procedures in the decision making 
process of the clinical management of patients  
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Legends to the figures 
 
Figure 1 | Total annual microRNA (miRNA) publications indexed in the PubMed 
database relating to urological tumours. The literature search was performed for the 
period from 2010 to February 2016.  
 
Figure 2 | The origin of the circulating microRNAs (miRNAs). MiRNAs are secreted 
by cells via specific regulated pathways. Exosomes are secreted when multivesicular 
bodies fuse with the plasma membrane. Microvesicles are formed by outward bulging 
of the cell membrane. Apoptotic bodies are formed at the late stage of apoptosis via 
membrane blebbing and contain cytoplasmic and nuclear components of the cells. 
miRNA can also be secreted bound to ribonucleoprotein complexes. The main 
protein binding partners are Argonaute proteins15, but they can also bind to other 
proteins such as high-density lipoproteins16 and nucleophosmin.17 Freely circulating 
miRNAs can be detected, which are either directly released by cancer cells or by 
vesicles, for example apoptotic bodies. 
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Table 1 | Studies regarding miRNAs in urine and blood as potential biomarkers 
in bladder cancer  
 
Reference 
(year) 
Study with 
marker 
development 
phases, 
number of 
patients and 
controls * 
Sample Method; 
reference 
method ‡ 
Significant 
miRNA 
expression§ 
Clinically relevant 
findings|| 
Urine      
Hanke et al. 
(2010)34 
Discovery: 27 
patients (nine 
G1, nine 
G2/3, nine 
urinary tract 
infections), 
nine controls 
Validation: 29 
patients (11 
G1, 18 G2/3, 
9 infections), 
11 controls 
Whole-urine Discovery: 
TaqMan array 
(Early access 
kit, 157 
miRNAs) 
Validation: 
RT-qPCR 
(TaqMan); 
miR-152 
miR-126 ↑ 
miR-182 ↑ 
Diagnosis of cancer with 
miR-126: miR-182 ratio 
as best indicator: 
(AUC = 0.768, 
DS = 72%, DSp = 82%) 
Yamada et 
al. (2011)35 
100 patients 
74 controls 
(healthy 
adults, some 
with urinary 
tract infection) 
Urine 
sediment 
RT-qPCR 
(TaqMan); 
absolute 
quantification 
miR-96 ↑ 
miR-183 ↑ 
Diagnosis of cancer with 
miR-96 (AUC = 0.831, 
DS = 71%, DSp = 79%) 
and miR-183 
(AUC = 0.817, 
DS = 74%, DSp = 77%) 
Miah et al. 
(2012)36 
68 patients 
(with new or 
recurrent 
cancer) 
53 age-
matched 
controls 
Urine 
sediment 
RT-qPCR 
(TaqMan); 
RNU44 and 
RNU48 
miR-15b ↑ 
miR-135b ↓ 
miR-1224-3p↑ 
Diagnosis of cancer 
using the three miRNAs: 
(AUC = 0.86,DS = 94.1, 
DSp = 51%) 
Puerta-Gil et 
al. (2012)37 
37 patients 
57 controls 
(healthy 
adults, benign 
urological 
diseases) 
Urine (fraction 
not defined) 
RT-qPCR 
(TaqMan); 
miR-16 
miR-143 ↓ 
miR-222 ↑ 
miR-452 ↑ 
Diagnosis of cancer with 
miR-222 (AUC = 0.718) 
and miR-452 
(AUC = 0.848) 
Snowdon et 
al. (2012)38 
Eight patients  
Five controls 
Whole-urine RT-qPCR 
(TaqMan); 
RNU6B 
miR-125b ↓ 
miR-126 ↑ 
Without AUC data 
Wang et al. 
(2012)39 
51 patients 
24 subjects 
with negative 
cystoscopy 
results 
Urine 
sediment and 
supernatant 
RT-qPCR 
(TaqMan); 
RNU48 
miR-200 family 
miR-141 ↓ 
miR-200a ↓ 
 miR-200b ↓ 
 miR-200c ↓ 
miR-429 ↓ 
Differentiation between 
study groups only with 
sediment data: 
AUC = 0.706–0.804 and 
for miR-200a 
DS = 100% and 
DSp = 53% 
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Yun et 
al. (2012)40 
207 patients 
(138 with 
NMIBC and 
69 with MIBC) 
144 controls 
Urine 
supernatant 
RT-qPCR 
(Qiagen); 
RNU6 
miR-145 ↓ 
miR-200a ↓ 
Diagnosis of NMIBC 
and MIBC with miR-145: 
AUC = 0.729 and 0.790, 
DS = 78% and 84%, 
DSp = 61% and 61% 
Prognostic marker: miR-
200a as an independent 
marker for NMIBC 
recurrence 
Kim et al. 
(2013)41 
138 NMIBC  
144 controls 
Urine 
supernatant 
RT-qPCR 
(Qiagen); 
RNU6 
miR-214 ↑ Diagnosis of cancer and 
prognostic marker for 
NMIBC recurrence 
Mengual et 
al. (2013)42 
Discovery: 30 
patients and 
10 controls 
Validation: 
151 patients 
and 121 
patients with 
twothirds as a 
training set 
and onethird 
as a test set 
Urine 
sediment 
(from 50-100 
ml urine) 
Discovery: 
TaqMan array 
Validation: 
RT-qPCR 
(Exiqon); 
miR-30c and 
miR-103 
Panel 1: miR-
18a* ↑ 
miR-25 ↑ 
miR-187 ↑ 
miR-140-5p ↓ 
miR-142-3p ↓ 
miR-204 ↓ 
Panel 2: 
miR-125b ↓ 
miR-92a ↑ 
Diagnosis of cancer with 
panel 1: (AUC = 0.92, 
DS = 85%, DSp = 87%) 
Discrimination between 
low-grade and high-
grade tumours with 
panel 2: AUC = 0.83, 
DS = 85%, DSp = 74% 
Shimizu et 
al. (2013)43 
Discovery: 86 
patients, 20 
individuals 
without 
cancer 
Validation: 
training set 
with 86 
patients and 
test set with 
34 patients 
Urine 
sediment 
  
Methylation-
specific PCR, 
bisulfite 
sequencing 
and bisulfite 
pyrosequen-
cing 
Methylated 
miRs 
miR-9-3 ↓ 
miR-124-2 ↓ 
miR-124-3 ↓ 
miR-137 ↓ 
 
Diagnosis of cancer 
using the combined 
miRNAs: AUC = 0.91 
Detection of Ta stage 
and low grades G1 and 
G2: AUC = 0.862, 
DS = 68%, DSp = 89% 
 
Tölle et al. 
(2013)44 
Discovery: 
Eight patients 
and four 
healthy 
controls 
Validation: 36 
patients and 
19 controls 
Whole-urine Discovery: 
TaqMan array 
Validation: 
RT-qPCR 
(Qiagen); 
absolute 
quantification  
miR-520e ↑ 
miR-618 ↑ 
miR-1225-5p ↑ 
Diagnosis of cancer: 
AUC = 0.679–0.764 
Zhang et al. 
(2014)45 
Discovery: Six 
patients and 
three controls 
Validation: 50 
patients and 
21 controls 
Urine 
supernatant 
Discovery: 
Agilent array, 
Validation: 
RT-qPCR 
(Exiqon); 
RNU6B 
miR-99a ↓ 
miR-125b ↓ 
Diagnosis of cancer with 
both miRNAs in a 
logistic model: 
AUC = 0.876, 
DS = 87%, DSp = 82% 
Discrimination between 
G1 and G≥2 tumours : 
AUC = 0.831, 
DS = 79%, DSp = 88% 
Zhou et al. 
(2014)46 
112 patients 
78 controls 
Urine 
supernatant 
RT-qPCR 
(Qiagen); 
RNU6 
miR-106b ↑ Diagnosis of cancer: 
AUC = 0.802, 
DS = 76.8%, 
DSp = 72.4% 
Suggested as tumour 
recurrence marker after 
surgery 
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Eissa et al. 
(2015)47 
94 patients 
90 controls 
(including 30 
with benign 
bladder 
lesions) 
Urine 
sediment 
RT-qPCR 
(Qiagen); 
RNU6 
miR-96 ↑ Diagnosis of cancer: 
AUC = 0.822, 
DS = 72.3%, 
DSp = 88.9% 
Eissa et al. 
(2015)48 
Prospective 
study 
combined 
with other 
tests: 94 
patients, 
56 with 
negative 
cystoscopy 
results with 
benign urinary 
conditions 
and 
60 healthy 
controls  
Urine 
sediment 
RT-qPCR 
(Qiagen); 
RNU6 
miR-210 ↑ 
miR-96 ↑ 
Diagnosis of cancer with 
miRNAs combined with 
cytology and lncRNA-
UCA1: AUC = 0.933, 
DS = 100%, 
DSp = 89.5% 
 Reduction of false-
negative urine cytology 
results from 49% to 0% 
Liu et 
al. (2015)49 
78 patients 
who 
underwent 
lymph node 
dissection (23 
positive 
nodes, 54 
negative 
nodes)  
Urine 
sediment 
RT-qPCR 
(TaqMan); 
RNU6 
miR-141 ↓ 
miR-200b ↓ 
Prediction of positive 
lymph nodes by 
combined use of 
miRNAs and cancer 
stage: AUC = 0.749, 
better than CT staging: 
AUC = 0.679 
Long et al. 
(2015)50 
Prospective 
study 
Discovery: 
pooled 
samples from 
3 groups of 
85 patients 
versus 2 
groups of 45 
controls 
Validation: 85 
patients, 45 
controls 
Urine 
supernatant, 
exosomes 
Discovery: 
Exiqon array 
Validation: 
RT-qPCR 
(Exiqon); 
absolute 
quantification 
 
let-7b ↑ 
miR-15a ↑ 
miR-21 ↑ 
miR-26a ↑ 
miR-93 ↑ 
miR-191 ↑ 
miR-200c ↑ 
miR-940 ↑ 
Diagnosis with the panel 
of miR-26a, miR-93, 
miR-191, miR-940: 
AUC = 0.858, 
SD = 70%, DSp = 84%, 
partly subgroup 
differentiation 
Different miRNA 
expression in exosomes 
versus urine, clinical 
information not reported 
Wang et al. 
(2015)51 
Multicentre 
study 
292 patients 
(148 with 
NMIBC and 
144 with 
MIBC) and 
169 controls 
Urine 
supernatant 
RT-qPCR 
(Takara); 
RNU6 and 
RNU48 
miR-214 ↓ Diagnosis of cancer: 
AUC = 0.838, 
DS = 90.5%, 
DSp = 65.6% 
Diagnosis of NMIBC 
and MBIC: 
AUC = 0.657and 0.927, 
DS = 58% and 90.5%, 
DSp = 71% and 83% 
Prognostic marker for 
overall and recurrence 
free survival, but not 
independent 
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Sapre et al. 
(2016)52 
 
Discovery: 30 
patients with 
nonrecurrent 
disease , 30 
with recurrent 
disease and 
21 controls 
Validation: 25 
patients with 
cancer and 25 
patients 
without 
cancer in a 
surveillance 
study 
Whole-urine RT-qPCR 
(TaqMan); 
osmolarity 
adjusted 
miR-16 ↑ 
miR-21 ↑ 
miR-34a ↑ 
miR-200c ↑ 
miR-205 ↑ 
miR-221 ↑ 
Monitoring marker set: 
prediction of recurrence 
with AUC = 0.74, 
DS = 88%, 
DSp = 48%Reduced 
cystoscopy rate by 30% 
Whole-blood      
Tölle et al. 
(2013)44 
Discovery: 
Eight patients, 
four healthy 
controls 
Validation: 38 
patients, 20 
controls 
Whole-blood 
(PAXgene) 
Discovery: 
TaqMan array 
Validation: 
RT-qPCR 
(Qiagen); 
absolute 
quantification 
miR-26b-5p ↑ 
miR-144-5p ↑ 
miR-374-5p ↑ 
Diagnosis of BC: 
AUC = 0.774–0.824 
Serum      
Scheffer et 
al. (2014)53 
Discovery: 11 
patients with 
NMIBC, 11 
patients with 
MIBC and 10 
controls 
Validation: 65 
patients with 
NMIBC, 61 
patients with 
MIBC and 
105 controls 
(with 
nonmalignant 
urological 
disease) 
Serum RT-qPCR 
(Qiagen); 
cel-miR-39 
miR-141 
miR-639 
No different levels 
between study groups 
Jiang et al. 
(2015)54 
Discovery: 
pooled 
samples from 
10 patients 
with NMIBC, 
10 patients 
with MIBC, 10 
healthy 
controls 
Validation: 
Training 
set;120 
patients and 
120 controls 
and validation 
set; 110 
patients and 
110 controls 
Serum Discovery: 
Sequencing 
(Illumina) 
Validation: 
RT-qPCR 
(Takara); 
miR-16-5p 
and miR-193-
5p 
miR-152 ↑ 
miR-1486-3p ↑ 
miR-3187-3p ↓ 
miR-15b-5p ↓ 
miR-27a-3p ↓ 
miR-30a-5p ↓ 
Diagnosis of BC with all 
miRNAs: AUC = 0.899, 
DS = 80%, DSp = 89%; 
differentiation of NIMBC 
versus MIBC: 
AUC = 0.841, 
DS = 90%, DSp: 66.4% 
Prognostic marker set 
miR-152 and miR-3187-
3p: recurrence free 
survival for NIMBC, not 
for MIBC 
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Kriebel et al. 
(2015)55 
34 patients 
with upper 
urinary tract 
urothelial 
cancer 
34 controls 
Serum RT-qPCR 
(Qiagen); 
RNU1-4 and 
SNORD43 
miR-141 ↑ 
from 10 
miRNAs 
studied  
Diagnosis of cancer: 
AUC = 0.726, 
DS = 70.5%, 
DSp = 73.5% 
Plasma      
Adam et al. 
(2013)56 
20 patients 
18 controls 
EDTA-plasma RT-qPCR 
(TaqMan); 
RNU6 
No individual 
miRNA different 
between 
patients and 
controls 
Differentiation only with 
machine learning 
procedure 
Feng et al. 
(2014)57 
50 patients 
50 controls 
EDTA-plasma RT-qPCR 
(TaqMan); 
RNU6 
miR-99a ↓ Diagnostic marker: no 
information concerning 
diagnostic accuracy 
Feng et al. 
(2014)58 
50 patients 
50 controls 
EDTA-plasma RT-qPCR 
(TaqMan); 
RNU6 
miR-19a ↑ Diagnostic marker: no 
information concerning 
diagnostic accuracy 
Du et al. 
(2015)59 
Discovery: 
Pools of 10 
patients and 
10 controls 
Validation: 
Training set 
with 56 
patients and 
60 controls 
and test set 
with 109 
patients and 
115 controls 
EDTA-plasma Discovery: 
TaqMan array 
Validation: 
RT-qPCR 
(TaqMan); 
miR-16 
miR-497 ↓ 
miR-663b ↑ 
Diagnosis of cancer with 
the two combined 
miRNAs: AUC = 0.711, 
DS = 69.7%, 
DSp = 69.6% 
Other      
Armstrong et 
al. (2015)60 
214 NMIBC 
Two MIBC 
Matched 
tissue 
Plasma 
White blood 
cells 
Urine 
exosomes 
Discovery: 
NanoString 
profiling 
Validation: 
RT-qPCR 
(TaqMan); 
digital PCR  
25 different 
upregulated 
miRNAs 
ifferent miRNA 
relationships between 
matched samples; six 
miRNAs (miR-21-5p, 
miR-29b-3p, miR-200c-
3p, miR-200b-3p, miR-
205-5p and miR-4454) 
commonly upregulated 
in cancer tissue and 
urine exosomes  
*Development phases refer to definitions given in Table 1. ‡Manufacturer's name of the 
assay is given in brackets. §Significant ↑, ↓, upregulated and downregulated miRNAs in 
patients in comparison to controls or the comparison cohort. ||Relationship between 
dysregulated miRNAs and clinical question. miRNAs highlighted in bold are haemolysis-
affected according to MacLellan et al.61 AUC, area under the receiver operating 
characteristics curve; DS, diagnostic sensitivity; DSp, diagnostic specificity. EDTA, 
ethylenediaminetetraacetic acid; miRNA, microRNA; MIBC, muscle-invasive bladder cancer, 
NMIBC, non-muscle-invasive bladder cancer; RT-qPCR, reverse-transcription quantitative 
polymerase chain reaction. 
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Table 2 | Studies regarding miRNAs in blood and urine and blood samples as 
potential biomarkers renal cell carcinoma 
 
Reference 
(year) 
Study with marker 
development phases, 
number of patients and 
controls* 
Sample Method; 
reference 
method‡ 
Significant 
miRNA 
expression§ 
Clinically relevant findings|| 
Urine      
von 
Branden-
stein et al. 
(2012)65 
18 patients (7 ccRCC, 6 
pRCC and 5 chRCC) 
25 controls (oncocytoma, 
urological diseases, other 
tumours) 
Whole-
urine 
RT-qPCR 
(TaqMan); 
5S rRNA 
miR-15a ↑ Significantly increased versus 
controls, but no further 
diagnostic data reported 
Whole-
blood 
     
Schmitt et 
al. (2012)66 
43 patients (Wilms 
tumour) 
19 controls (healthy 
adults) 
Whole-
blood 
(PAXgene) 
RT-qPCR 
(Qiagen); 
RNU6B 
miR-520d-3p 
↑ 
miR-197 ↑ 
miR-224 ↑ 
miR-20a ↓ 
miR-126 ↓ 
miR-144* ↓ 
Diagnosis of RCC using the six-
miRNA signature: AUC = 0.97, 
DS = 99.1%, DSp = 94.8% 
Serum      
Wulfken et 
al. (2011)67 
Multicentre study. 
Discovery: six ccRCC 
patients, six controls 
Validation: 84 patients 
(69 ccRCC, 10 pRCC, 
three chRCC, two sRCC), 
93 controls 
Serum Discovery: 
TaqMan array  
Validation: 
RT-qPCR 
(TaqMan); 
cel-miR-39 
miR-1233 ↑ Diagnosis of RCC: 
AUC = 0.588, DS = 77.4%, 
DSp = 37.6% 
Redova et 
al. (2012)68 
Discovery: 15 ccRCC, 12 
controls 
Validation: 90 patients 
(73 ccRCC, eight pRCC, 
nine chRCC), 35 controls 
(blood donors) 
Serum Discovery: 
TaqMan array 
Validation: 
RT-qPCR 
(TaqMan); 
miR-16 
miR-378 ↑ 
miR-451 ↓ 
miR-150; ↓  
Diagnosis of RCC using the 
two-miRNA signature miR-378 
and miR-451: AUC = 0.86, 
DS = 81%, DSp = 83% 
Cheng et 
al. (2013)69 
12 ccRCC  
12 controls (benign 
kidney lesions) 
Serum RT-qPCR 
(Takara); 
RNU6 
miR-21 ↑ 
miR-141 ↓ 
miR-224 ↑ 
Significant changes compared 
with controls, but no further 
diagnostic data reported 
Zhao et 
al. (2013)70 
68 ccRCC  
42 healthy controls 
Serum RT-qPCR 
(Qiagen); 
5S rRNA 
miR-210 ↑ Diagnosis of RCC: 
AUC = 0.874, DS = 81%, 
DSp = 79.4% 
Iwamoto et 
al. (2014)71 
34 ccRCC  
23 healthy controls 
Serum RT-qPCR 
(TaqMan); 
miR-16 
miR-210 ↑ Diagnosis of RCC: AUC = 0.77, 
DS = 65%, DSp = 83% 
Fedorko et 
al. (2015)72 
195 patients (157 ccRCC, 
26 pRCC, 12 chRCC) 
100 controls (blood 
donors) 
Serum RT-qPCR 
(TaqMan); 
absolute 
quantification 
miR-378 ↑ 
miR-210 ↑ 
Diagnosis of RCC: AUC = 0.85, 
DS = 80%, DSp = 78% 
Suggested as a monitoring 
marker 
Ludwig et 
al. (2015)73 
43 patients 
(Wilms tumour) 
13 controls 
Serum 
(haemoly-
sis control 
performed) 
RT-qPCR 
(Qiagen); 
cel-miR-39 
miR-100-5p↑ 
miR-130b-
3p ↑ 
Diagnosis of cancer using the 
two-miRNA signature: 
AUC = 0.796, DS = 69.2%; 
DSp = 90% 
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Wang et al. 
(2015)74 
Discovery: 25 ccRCC, 25 
controls 
Validation: 107 ccRCC, 
107 controls (training set: 
28 of each; test set: 79 of 
each) 
Serum Discovery: 
TaqMan array  
Validation: 
RT-qPCR 
(TaqMan); 
let-7d/g/i 
miR-193-3p↑ 
miR-362 ↑ 
miR-572 ↑ 
miR-28-5p ↓ 
miR-378 ↓ 
Diagnosis of ccRCC: 
AUC = 0.807, DS = 80%, 
DSp = 71% 
Plasma      
Teixeira et 
al. (2014)75 
43 RCC  
34 controls 
Plasma RT-qPCR 
(TaqMan); 
RNU44 
miR-221 ↑ Diagnosis of RCC: 
AUC = 0.696, DS = 72.5%, 
DSp = 33.3% 
Prognosis of overall survival: 
independent marker; increase 
of C-index for TNM stage, 
Fuhrman grade and age from 
0.800 to 0.961 
Other      
Gamez-
Pozo et al. 
(2012)76 
Prospective cohort study: 
38 carcinoma patients 
(advanced stage) treated 
with sunitinib; discovery 
and validation phases 
Leuco-
cytes 
(Leuko-
LOCK) 
Discovery: 
Agilent array  
Validation: 
RT-qPCR 
(Exiqon); 
mean of miR-
103 and miR-
191 
miR-192 
miR-193a-3p 
miR-410 
miR-424* 
miR-501-3p 
miR-1181 
Predictive models of response 
to sunitinib treatment: 
for poor response with miR-192, 
miR-193a-3p, miR-501-3p; for 
prolonged response with 
miR-410, miR-424*, miR-1181 
 
 *Development phases refer to definitions given in Box 2. ‡Manufacturer's name of the assay 
is given in brackets. §Significant ↑, ↓, upregulated and downregulated miRNAs in patients in 
comparison to controls or the comparison cohort. ||Relationship between dysregulated 
miRNAs and clinical question. miRNAs highlighted in bold letters are haemolysis-affected 
according to MacLellan et al.61 AUC, area under the receiver operating characteristics curve; 
cc, clear cell; ch, chromophobe; EDTA, ethylenediaminetetraacetic acid; DS, diagnostic 
sensitivity; DSp, diagnostic specificity; miRNA, microRNA; p, papillary; RCC, renal cell 
cancer; RT-qPCR, quantitative real-time reverse-transcription polymerase chain reaction; s, 
sarcomatoid. 
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Table 3 | Studies regarding urine and blood as potential biomarkers in prostate 
cancer 
 
Reference 
(year) 
Study with marker 
development 
phases, number of 
patients and 
controls* 
Sample Method;  
reference 
method‡ 
Significant 
miRNA 
expression§ 
Clinically relevant findings|| 
C 
Urine      
Ahumada-
Tamayo et 
al. (2011)83 
Nine patients with 
prostate cancer 
Nine patients with 
BPH 
Urine 
sediment 
after prostate 
massage 
TaqMan array 21 differentially 
expressed 
miRNAs 
Diagnosis of prostate cancer: 
19 miRNAs were twofold 
higher and two miRNAs 
twofold lower in BPH than in 
prostate cancer; no further 
diagnostic data were given 
Bryant et 
al. (2012)84 
70 patients with 
localized and 40 
advanced prostate 
cancer, 17 controls 
(not defined) 
Urine 
sediment 
after DRE 
RT-qPCR 
(TaqMan); 
mean of 
RNU44 and 
RNU48 
miR-107 ↑ 
miR-574-3p ↑ 
Diagnosis of prostate cancer 
and/or prediction of prostate 
biopsy result: both miRNAs 
discriminate cancer better 
than PCA3 (AUCs of 0.74 
and 0.66 versus 0.61) 
Srivastava 
et al. 
(2013)85 
36 patients with 
prostate cancer 
12 healthy men 
Whole-urine 
(collection not 
described) 
RT-qPCR 
(TaqMan); 
RNU48 
miR-205 ↓ 
miR-214 ↓ 
Diagnosis of prostate cancer 
and/or of positive prostate 
biopsy result: combined use: 
DS = 89%, DSp = 80%; no 
comparator test was given 
Casanova-
Salas et al. 
(2014)86 
45 patients with 
cancer-positive biopsy 
47 patients with 
negative biopsy  
Urine 
sediment 
after DRE 
RT-qPCR 
(TaqMan); 
mean of 
RNU44 and 
RNU48 
miR-182 ↑ 
miR-187 ↓ 
Diagnosis of cancer and/or 
prediction of positive biopsy: 
combination of miR-187, PSA 
and PCA3 (AUC = 0.711) 
better than PSA alone 
(AUC = 0.615)  
Haj-Ahmad 
et al. 
(2014)87 
Discovery: pooled 
samples from eight 
patients with prostate 
cancer, 12 with BPH 
and 10 healthy men 
Validation: selected 
miRNAs in all 
individual samples  
Whole-urine  Discovery: 
LC Science 
Paraflo array 
Validation: RT-
qPCR 
(TaqMan); 
5S rRNA 
miR-484  
miR-1825 ↑ 
Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: combination of 
both miRNAs: DS = 45%, 
DSp = 75%, not better than 
PSA 
Sapre et 
al. (2014)88 
Discovery: 17 patients 
with low-risk and 16 
with high-risk cancer 
Validation: 22 patients 
with high-risk and 14 
with indolent prostate 
cancer  
Whole-urine 
after DRE 
TaqMan array 
and RT-qPCR; 
global mean 
approach 
miR-16 ↑  
miR-20a ↑ 
miR21 ↑ 
 miR-34a ↑ 
miR-106b ↑ 
miR-145 ↑ 
miR-182 ↑ 
miR-205 ↑ 
miR-221 ↑ 
miR-222 ↑ 
miR-331 ↑ 
miR-375 ↑ 
miR-218 ↓ 
(selected miRs 
as published at 
least in two 
studies) 
Prediction of lethal from 
indolent prostate cancer at 
radical prostatectomy: 
discrepant data, optimal 
combination miR-16, miR-21 
and miR-222 in the discovery 
phase with AUC = 0.73, but 
only 0.35 in the validation 
phase 
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Yun et al. 
(2014)89 
Discovery: 14 patients 
with prostate cancer 
and five with BPH 
Validation: 463 
patients with prostate 
cancer and 302 with 
BPH in three 
validation cohorts and 
a biopsy cohort of 150 
patients 
First morning 
urine 
supernatant 
Discovery: 
Agilent array 
Validation: 
RT-qPCR 
(Qiagen); 
total RNA input 
miR-615-3p ↑ 
miR-4316 ↑ 
hsv1-miR-H18 
↑ 
hsv2-miR-H9-
5p ↑ 
Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: both virus 
encoded miRNAs had higher 
AUCs (0.761 and 0.738) than 
PSA (0.613) within the PSA 
gray zone (3–10 ng/ml) 
Suggested combination: PSA 
and hsv2-miR-H9-5p  
Egidi et 
al. (2015)90 
41 patients with 
localized prostate 
cancer 
38 patients with BPH 
with negative biopsies 
Urine 
sediment 
after DRE 
RT-qPCR 
(Qiagen); 
miR-191 
miR-9-3p ↓ 
miR-19a-3p ↓ 
Diagnosis of prostate cancer 
and/or prediction of positive 
prostate biopsy result: both 
miRs with AUCs of 0.769 and 
0.723, respectively, but urine 
PSA mRNA was better 
(0.837); best combination 
urine PSA mRNA plus miR-
19a-3p with an AUC of 0.880 
Korznenie-
wski et al. 
(2015)91 
71 patients with 
prostate cancer 
18 men with prostate 
negative biopsy 
Urine 
supernatant, 
without DRE 
RT-qPCR 
(TaqMan); 
cel-miR-39 
miR-483-5p ↑ 
miR-1275 
miR-1290 
Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: only miR-483-
5p discriminated 
(AUC = 0.694), but serum 
PSA (AUC = 0.81) was 
better; no improvement using 
combination of PSA and miR-
483-5p 
Stephan et 
al. (2015)92 
38 patients with 
cancer-positive biopsy 
patients  
38 patients with 
negative biopsy 
Urine 
sediment 
after DRE 
RT-qPCR 
(TaqMan); 
total RNA 
input, PSA 
mRNA, miR-
130b 
miR-183 
miR-205 
Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: no 
differentiation between both 
cohorts, but discrimination 
with Progensa and own 
PCA3 tests 
Whole-
blood 
     
Santos et 
al. (2014)93 
45 patients with 
CRPC  
 
Whole-blood 
and isolation 
of white 
fraction 
RT-qPCR 
(TaqMan); 
RNU44 
miR-7 ↑ 
miR-221 ↑ 
Prediction of patients with 
early castration resistance, 
response to therapy and 
overall survival 
Leidinger 
et al. 
(2016)94 
Discovery: 115 
patients with prostate 
cancer and 39 with 
BPH  
Validation: 15 patients 
with prostate cancer 
and 15 with BPH  
Whole-blood 
(PAXgene) 
Discovery: 
Geniom 
Biochip array, 
Validation: RT-
qPCR 
(Qiagen); 
RNU48 
miR-659 ↑ 
miR-675 ↑ 
miR-1180 ↑ 
miR-1225 ↑ 
miR-221* ↓ 
miR-518-5p ↓ 
miR-708* ↓ 
Differences were reported 
without conclusive data of 
diagnostic accuracy and 
preoperative risk 
Serum      
Mitchell et 
al. (2008)20 
25 patients with 
metastatic prostate 
cancer 
25 healthy men 
Serum RT-qPCR 
(TaqMan);  
cel-miR-39, 
miR-54 and 
miR-238 
miR-100 ↑ 
miR-125 ↑  
miR-141 ↑ 
miR-143 ↑ 
miR-205 ↑ 
miR-296 ↑ 
First report on circulating 
miRNAs, their stability in 
blood and difference between 
patients and healthy men: 
best discrimination by miR-
141 ↑ (AUC = 0.907) 
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Lodes et 
al. (2009)95 
Six patients with 
prostate cancer 
Eight controls 
Serum In-house 
microarray 
15 miRNAs  Diagnostic data not reported 
for patients 
Brase et al. 
(2011)96 
Discovery: Seven 
patients with 
metastatic prostate 
cancer, 14 with 
localized prostate 
cancer 
Validation: two 
cohorts patients with 
prostate cancer of 
different risk status 
(n = 45 and 71) 
Serum Discovery: 
TaqMan array 
Validation: RT-
qPCR 
(TaqMan); 
cel-miR-9, 
miR-54 and 
miR-238 
miR-141 ↑ 
miR-375 ↑ 
 
Prognosis: prediction of 
patients with high-risk cancer. 
Increased miRNAs 
corresponded to 
cliniocpathological end points 
and were helpful in prediction 
of high risk patients  
Mahn et al. 
(2011)97 
45 patients with 
prostate cancer, 18 
with BPH and 
20 healthy men 
Serum RT-qPCR 
(TaqMan); 
cel-miR-39 
let-7i ↑ 
miR-26a ↑ 
miR-32 ↑ 
miR-195 ↑ 
Combined use of all four 
miRs: AUC = 0.758, but not 
better than PSA 
(AUC = 0.834) 
Moltzahn 
et al. 
(2011)98 
Three groups of 12 
patients with prostate 
cancer with different 
risk statuses 
12 healthy blood 
donors 
Serum Discovery: 
TaqMan array 
Validation:  
RT-qPCR 
(TaqMan); 
global median 
approach 
miR-20b ↑ 
miR-93 ↑ 
miR-106a ↑  
miR-874 ↑ 
miR-1207-5p ↑ 
miR-1274a ↑  
miR-24 ↓ 
miR-26b ↓ 
 miR-30c ↓ 
miR-223 ↓ 
Discrimination of prostate 
cancer and controls: miRNAs 
↓ and miRNA ↑ with 
AUC = 0.78–0.93. 
Prognostic ability: miR-93, 
miR-106, miR-242 for 
patients with high-risk cancer 
Selth et al. 
(2011)99 
25 patients with 
metastatic prostate 
cancer 
25 healthy men 
(selected miRNAs 
from profiling in a 
mouse model) 
Serum RT-qPCR 
(TaqMan); 
cel-miR-39 
miR-141 ↑ 
miR-298 ↑ 
miR-346 ↑ 
miR-375 ↑ 
miR-141, miR-298, miR-346, 
miR-375 were increased in 
patients with metastatic 
prostate cancer; but no 
diagnostic data were 
presented 
Zhang et 
al. 
(2011)100 
56 patients with 
prostate cancer and 
six with BPH  
Serum RT-qPCR 
(TaqMan); 
RNU6 
miR-21 ↑ miR-21 ↑ in metastatic, but 
not in localized prostate 
cancer 
Cheng et 
al. 
(2013)101 
Discovery: pools from 
25 patients with 
metastatic CRPC and 
25 healthy men 
Validation: 21 patients 
with prostate cancer 
and 20 healthy men 
Serum Discovery: 
TaqMan array 
Validation: RT-
qPCR 
(TaqMan); 
absolute 
quantification 
miR-141 ↑ 
miR-200a ↑ 
miR-200c ↑ 
miR-210 ↑ 
miR-375 ↑ 
Discrimination between 
healthy men and metastatic 
patients by the five miRNAs: 
AUC = 0.638–0.899); no 
comparison to standard 
factors were given; miR-210 
like PSA in relation to 
androgen deprivation therapy 
Egidi et al. 
(2013)102 
38 patients with 
prostate cancer before 
and after radical 
prostatectomy 
40 healthy controls 
Serum RT-qPCR 
(Exiqon); 
miR-93 
miR-21 ↔ 
miR-141 ↓ 
miR-21: no difference 
between prostate cancer and 
controls; miR-141: lower 
levels in patients than in 
controls 
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Nguyen et 
al. 
(2013)103 
28 patients with low-
risk prostate cancer,  
30 with high-risk 
prostate cancer and 
26 with metastatic 
CRPC 
 
Serum Discovery: 
TaqMan  array 
Validation:  
RT-qPCR 
(TaqMan);  
RRNU6 
miR-141 ↑ 
miR-375 ↑ 
miR-378 ↑ 
miR-409-3p ↓ 
Prediction of low-risk and 
metastatic cancer: with 
different levels of all four 
miRNAs. Data as real 
prognostic markers were not 
given 
Selth et al. 
(2013)104 
Discovery: 
eight patients with and 
without biochemical 
relapse  
Validation: 31 versus 
39 patients with and 
without relapse 
Serum Discovery: 
TaqMan array 
Validation:  
RT-qPCR 
(TaqMan)  
cel-mir-39 
miR-141 ↑ 
miR-146b-3p ↑ 
miR-194 ↑  
miR-375 ↑ 
Prediction of biochemical 
relapse: miR-146b-3p and 
miR-194 predicted 
recurrence in univariate, miR-
146b-3p in multivariate 
analysis with standard 
clinicopathological factors 
Zhang et 
al. 
(2013)105 
20 patients with 
localized prostate 
cancer, 30 patients 
with bone-metastatic 
prostate cancer and 
six with BPH 
Serum RT-qPCR 
(TaqMan); 
RNU6 
miR-141 ↑ No different miR-141 levels 
between BPH and localized 
cancer, but increased by 
bone metastasis 
Haldrup et 
al. 
(2014)106 
31 patients with 
localized or metastatic 
prostate cancer and 
13 with BPH 
Serum Exiqon panels 
I+II, without 
RT-qPCR; 
miR-320a 
11 miRNAs 
 
Diagnosis of prostate cancer 
and prediction of risk groups: 
only miR-103-2* as early 
diagnostic marker (BPH 
versus localized prostate 
cancer); other combinations 
to differentiate between BPH, 
localized and metastatic 
prostate cancer 
Kotb et al. 
(2014)107 
10 patients with 
positive and 10 with 
negative biopsy  
Serum RT-qPCR 
(TaqMan); 
SNORD47 
miR-21 ↑ 
miR-221 ↑ 
Predictors of positive prostate 
biopsy 
Singh et 
al. (2014)10
8  
Discovery: 
identification of 
prostate-cancer-
differentiating miRNAs 
in cell models 
Validation: 62 patients 
after prostatectomy 
with and without 
biochemical 
recurrence 
(>4.5 years) 
Serum RT-qPCR 
(Exiqon); 
overall mean 
miR-103 ↑ 
miR-125b ↑ 
miR-222 ↑ 
Prognosis of radical 
prostatectomy: prediction of 
biochemical relapse; 
combination of miR-103 and 
PSA as best model 
 
Wang et al. 
(2014)109 
Discovery: 48 patients 
with low-risk (Gleason 
score <7), 48 with 
higher-risk prostate 
cancer (Gleason 
score≥7) 
Validation: 35 patient 
with low-risk and 25 
with higher-risk 
prostate cancer 
Serum Fluidigm array; 
global median 
approach 
miR-19 ↑ 
miR-345 ↓ 
miR-519c-5p ↓ 
Surveillance biomarker: 
presurgical serum levels of 
miRNAs can identify patients 
with adverse Gleason score 
in postsurgical specimens 
independent of age, PSA, 
biopsy data (AUC = 0.94 
versus 0.77 for PSA)  
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Westerma
nn et al. 
(2014)110 
Multicentre study, 
prospective collection 
of samples. 
54 patients with 
positive biopsy and 79 
with negative biopsy 
Serum RT-qPCR 
(Qiagen); 
SNORD43 and 
RNU1-4 
miR-26a-1 
miR-141 
No difference in miRNA 
levels between patients with 
positive and negative 
biopsies; miR-141 dependent 
on Gleason score 
Mihelich et 
al. 
(2015)111 
50 patients with 
surgical 100% 
Gleason grade 3 and 
30-90% Gleason 
grade 4+5, with follow-
up monitoring after 
surgery 
50 with BPH with 
negative biopsy 
Serum RT-qPCR 
(Qiagen); 
cel-miR-39 and 
total RNA input 
21 miRNAs 
(selected 
miRNAs based 
on literature 
data) 
Prediction of Gleason grade: 
miR Score 1 and 2 with 14 
miRNAs for predicting low-
grade from high-grade 
prostate cancer, and BPH 
and low-grade cancer from 
high-grade cancer. 
Prediction of recurrence-free 
interval after prostatectomy: 
miR Risk Score with seven 
miRNAs  
Sun et al. 
(2015)112 
128 patients with 
prostate cancer in 
follow-up data after 
prostatectomy 
100 healthy controls 
Serum RT-qPCR 
(Takara); 
RNU6 
miR-128 ↓ Prediction of biochemical 
relapse in univariate and 
multivariate analyses 
Wach et al. 
(2015)113 
Integrated approach 
together with other 
biomarkers. 
146 patients with 
prostate cancer with 
follow-up data after 
radical prostatectomy, 
35 with BPH and 18 
healthy men 
Serum RT-qPCR 
(Exiqon); 
miR16 and 
RNU6b 
miR-375 ↑ Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: miR-375 alone 
(AUC = 0.720) or together 
with urokinase plasminogen 
activator receptor 
(AUC = 0.755) discriminated 
better than PSA 
(AUC = 0.603)  
Prognosis of overall survival: 
high levels of both 
parameters showed poor 
overall survival 
Plasma      
Agaoglu et 
al. 
(2011)114 
26 patients with 
localized prostate 
cancer,  
25 with metastatic 
prostate cancer and 
20 healthy men 
Plasma RT-qPCR 
(Qiagen); 
RNU1A 
miR-21 ↑ 
miR-141 ↑ 
miR-221 ↑ 
Discrimination of patients and 
healthy men using miR-21 
(AUC = 0.88); between 
metastatic and localized 
prostate cancer using miR-
141 (AUC = 0.755), but PSA 
with AUC = 0.865 
Gonzales 
et al. 
(2011)115 
21 patients with 
metastatic proste 
cancer in response to 
therapy (retrospective 
study) 
Plasma RT-qPCR 
(TaqMan) 
miR-141 ↑ Predictor of clinical outcome 
(progression) in response to 
therapy: concordant with PSA 
or circulating tumour cells 
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Chen et al. 
(2012)116 
Discovery: 25 patients 
with prostate cancer 
and 17 with BPH 
Validation: 80 patients 
with prostate cancer, 
44 with BPH and 54 
healthy men 
EDTA-plasma Discovery: 
Illumina 
miRNA array 
Validation:  
RT-qPCR 
(Qiagen); 
RNU6 
let-7c ↓ 
let-7e ↓ 
miR-30c ↓  
miR-622 ↑ 
miR-1285 ↑  
Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: discrimination 
between prostate cancer and 
BPH using upregulated and 
downregulated miRNAs: 
AUC = 0.644–0.805; 
combination of miR-30c or 
let-7e, with PSA: 
AUC = 0.886–0.969 
Shen et al. 
(2012)117 
82 patients with 
prostate cancer of 
different risk  
EDTA-plasma RT-qPCR 
(TaqMan);  
absolute 
quantification 
miR-20a ↑ 
miR-21 ↑ 
miR-145 ↑ 
miR-221 ↑ 
Prediction of high-risk and 
low-risk cancer with the set of 
four miRNAs: AUC = 0.763, 
DS = 29.4%, DSp = 97.4% 
Watahiki et 
al. 
(2013)118 
Discovery: pools from 
25 patients with 
localized prostate 
cancer and 25 with 
metastatic CRPC 
patients 
Validation: RT-qPCR 
with individual 
samples 
EDTA-plasma Discovery: 
Exiqon array 
Validation:  
RT-qPCR 
(Exiqon);  
miR-30e 
miR-21 ↑ 
miR-126 ↑ 
miR-141 ↑ 
miR-151-3p ↑ 
miR-152 ↑ 
miR-200c ↑ 
miR-375 ↑ 
miR-423-3p ↑ 
miR-16 ↓,  
miR-205 ↓ 
miRNAs discriminated 
between localized and 
metastatic CRPC 
(AUC = 0.75–0.88); but not 
better than PSA alone 
(AUC = 0.96); association of 
different miRNAs to prostate 
cancer progression,  
Medina-
Villaamil et 
al. 
(2014)119 
10 patients with low-
risk, nine with 
intermediate-risk, 11 
with high-risk prostate 
cancer  and 
10 healthy controls 
EDTA-plasma Discovery: 
Hexiqon array 
with 92 
miRNAs 
Validation:  
RT-PCR (not 
specfied) 
miR-10a 
miR-15b 
miR-124 
miR128 
miR-187 
miR-188-5p 
miR-196b 
miR-199b-5p 
miR-200b 
miR-218 
miR-330-3p 
miR-337-3p 
miR-339-3p 
Prediction of risk groups: all 
miRNAs were different 
between the risk groups; 
miR-187, miR-188-5p, miR-
196b together with clinical 
variables as best predictors 
of risk groups; detailed data 
were not given 
Sapre et 
al. (2014)88 
33 patients with low-
risk and 37 with high-
risk prostate cancer 
(selected 12 miRNAs 
published at least in 2 
studies) 
Plasma RT-qPCR 
(TaqMan); 
RNU48 
miR-16 
 
Prediction of low-risk and 
high-risk cancer: only miR-16 
out of 12 miRNAs 
differentiated risk groups, but 
with low AUC of 0.62 
Kachakova 
et al. 
(2015)120 
59 patients with 
prostate cancer, 16 
with BPH and 11 
young healthy men 
EDTA-plasma RT-qPCR 
(Qiagen); 
RNU6B 
let-7c ↓ 
miR-30c ↓ 
miR-141 ↓ 
miR-375 ↓ 
Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: miR-375 as 
best higher discriminator 
between prostate cancer and 
controls: AUC = 0.809, 
DS = 81.3%, DSp = 72.9%); 
better than PSA 
(AUC = 0.710, DS = 76.8%, 
DSp = 53.3%), both 
combined increased AUC to 
0.833 
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Kelly et al. 
(2015)121 
75 patients with 
prostate cancer and 
27 patients with 
negative biopsy 
EDTA-plasma RT-qPCR 
(TaqMan); 
miR-16 and 
miR-425 
let-7a 
miR-16 
miR-21 
miR-34a 
miR-141 
miR-143 
miR-145 
miR-125b 
miR-155 
miR-221 
miR-375 
miR-425  
Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy: combined use of miR-
141, miR-145, miR-155, let-
7a with AUC of 0.783 and 
DS = 97%; correlation with 
D'Amico risk stratification 
Chen et 
al. (2016)12
2 
65 patients with 
prostate cancer, 51 
with BPH patients and 
74 matched healthy 
men 
EDTA-plasma RT-qPCR 
(TaqMan); 
cel-miR-39 
miR-21 
miR-152 
Diagnosis of prostate cancer: 
no differences between the 
groups; unsuitable markers 
for early screening 
Other      
Bryant et 
al.  
(2012)84 
Discovery: 78 patients 
with prostate cancer 
and 28 healthy men 
Validation: individual 
RT-qPCRs, additional 
47 patients with and 
72 without recurrence 
after prostatectomy 
Circulating 
microvesicles 
from plasma 
or serum  
Discovery: 
Exiqon array 
Validation:  
RT-qPCR 
(TaqMan); 
cel-miR-39 
miR-107 ↑ 
miR-141 ↑ 
miR-200b ↑ 
miR-375 ↑ 
miR-574-3p ↑  
Different miRNA 
combinations with 
discrimination between 
controls and nonmetastatic 
prostate cancer: not better 
than PSA. Metastatic and 
nonmetastatic cancer can be 
differentiated by miR-141 
plus miR-375 (metastatic 
signature) 
Huang et 
al. 
(2015)123 
Prospective cohort 
study: 
75 patients with 
prostate cancer and 
follow-up data after 
surgery (25 with 
recurrence or 
metastasis, 50 
without) And 75 
healthy controls 
Peripheral 
blood 
mononuclear 
cells 
RT-qPCR 
(TaqMan); 
RNU6 
miR-21 Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: AUC = 0.833, 
DS = 87.5%, DSp = 85.7% 
 Marker in follow-up 
monitoring after surgery: high 
miRNA values corresponded 
with recurrence and 
metastasis 
Huang et 
al. 
(2015)124 
Discovery: 
23 patients with 
CRPC  
Validation: 100 
patients with CRPC 
for evaluation of 
overall survival  
Exosomes  
(EDTA-
plasma) 
Discovery: 
sequencing 
(Illumina) 
Validation:  
RT-qPCR 
(Qiagen); 
miR-30a-5p 
and miR-30e-
5p 
miR-375 ↑ 
miR-1290 ↑ 
Prognosis of overall survival:  
increased values of both 
miRNAs corresponded with a 
mortality of 80% at the 20-
month follow-up point; 
significantly improvement in 
clinical variable-based 
prediction model by the 
inclusion of both miRNAs 
Xu et al. 
(2015)125 
98 patients with 
prostate cancer and 
follow-up data after 
radical prostatectomy 
and 56 healthy men 
Peripheral 
blood 
mononuclear 
cells 
RT-qPCR 
(Takara); 
RNU6 
miR-129 ↓ Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: AUC = 0.846, 
DS = 88.9%, DSp=66.7% 
Prognosis: high miRNA 
values corresponded with 
poor recurrence-free interval  
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Li et al. 
(2016)126 
51 patients with 
prostate cancer (31 
with nonmetastatic, 
and 20 with metastatic 
disease) and 40 
healthy controls 
Exosomes 
(serum) and  
Serum  
RT-qPCR 
(Takara); 
cel-miR-39 
miR-141 ↑ Diagnosis of prostate cancer 
and/or prediction of positive 
biopsy result: higher levels in 
prostate cancer than in BPH 
both in serum and in 
exosomes; differentiation 
between metastatic and 
localized cancer with AUC of 
0.869 better than with PSA 
(AUC = 0.776) 
 
*Development phases refer to definitions given in Box 2. ‡Manufacturer's name of the assay 
is given in brackets. §Significant ↑, ↓, upregulated and downregulated miRNAs in patients in 
comparison to controls or the comparison cohort. ||Relationship between dysregulated 
miRNAs and clinical question. miRNAs highlighted in bold letters are haemolysis-affected 
according to MacLellan et al.61 AUC, area under the receiver operating characteristics curve; 
BPH, benign prostatic hyperplasia; CRPC, castration-resistant prostate cancer; DRE, digital-
rectal examination; DS, diagnostic sensitivity; DSp, diagnostic specificity; EDTA, 
ethylenediaminetetraacetic acid; RT-qPCR, reverse-transcription quantitative PCR. 
 


